Successful Enrolment Completed Across Two Cohorts

Summary by AI BETAClose X

Coiled Therapeutics plc has successfully completed patient enrolment in two initial cohorts of its new lipid-based softgel formulation of AO-252, a TACC3 inhibitor, with three patients enrolled in a 120mg twice-daily cohort and three patients in a 160mg once-daily cohort, all progressing as planned. This new formulation aims for more consistent, dose-proportional absorption, building on an 80% Clinical Benefit Rate observed with an earlier tablet formulation, and the company expects to dose up to 30 patients with the new formulation by year-end 2026 as it advances towards Phase I/II dose-expansion cohorts in ovarian and prostate cancer, with initial safety and pharmacokinetic data readouts anticipated by the end of 2026.

Disclaimer*

UK 100

Latest directors dealings